Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21052354 | 0.89 | TSHR (0.48) | TSHRSLC1A1KMT2AMEN1LMNA | |
| SCHEMBL21052370 | 0.87 | TSHR (0.46) | TSHRSLC1A1KMT2AMEN1LMNA | |
| SCHEMBL15237382 | 0.86 | TSHR (0.50) | TSHRSLC1A1 | |
| Adipic Acid SCHEMBL6636443 | 0.85 | TSHR (0.55) | TSHRSLC1A1LMNAALDH1A1L3MBTL1 | |
| SCHEMBL15237381 | 0.85 | TSHR (0.42) | TSHRSLC1A1KMT2AMEN1LMNA | |
| SCHEMBL3197402 | 0.82 | TSHR (0.53) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL6262034 | 0.81 | TSHR (0.40) | TSHRSLC1A1KMT2AMEN1LMNA | |
| SCHEMBL9606840 | 0.81 | TSHR (0.55) | TSHRSLC1A1KMT2AMEN1LMNA | |
| SCHEMBL13506382 | 0.81 | TSHR (0.42) | TSHRKMT2AMEN1CA12CA14 | |
| SCHEMBL5000221 | 0.81 | TSHR (0.55) | TSHRSLC1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758635-B2 | Radiopharmaceutical compositions | SERAC HEALTHCARE LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20130129623-A1 | RADIOPHARMACEUTICAL COMPOSITIONS | GE HEALTHCARE LIMTED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| WO-2007094683-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | TSHR 282/4885SLC1A1 837/4885KMT2A 3770/4885 |
| US-10758635-B2 | Radiopharmaceutical compositions | TYMP, KIT, CHEK1 | TSHR 2061/4885SLC1A1 3662/4885KMT2A 3149/4885 |
| US-20130129623-A1 | RADIOPHARMACEUTICAL COMPOSITIONS | TYMP, KIT, CHEK1 | TSHR 2061/4885SLC1A1 3662/4885KMT2A 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.